The Di Bella Method (DBM).
OBJECTIVE
the aim of the Di Bella Method (DBM) is to try to overcome the high toxicity level and the limited efficacy of the current medical treatments for cancer.


METHODS
using Melatonin, Retinoids, and vitamins E, D3, and C, components of the extracellular matrix, the DBM reinforces those means that Physiology considers essential for life. Acting together, these differentiating molecules also have an antiangiogenic and antiproliferative effect. Cabergoline and/or Bromocriptin negatively regulate Prolactin, the ubiquitary mitogenic hormone. This effect is reinforced by Somatostatin and/or its analogues by negatively regulating highly mitogenic molecules such as GH and GH-dependent growth factors.


RESULTS
the preliminary results are reported of a retrospective observational study on 553 patients treated with the DBM. These data show that the DBM achieved an evident improvement in the quality of life and a considerable increase in the mean survival rates for every disease and stage with respect to the data available in the literature relative to chemotherapy and/or monoclonal antibodies. The result was achieved without any of the known significant toxic effects of chemotherapy and (albeit to a lesser extent with respect to chemotherapy) of monoclonal antibodies. The invalidating causes which removed all scientific credibility from the DBM experiments carried out in Italy in 1998 are also reported.


CONCLUSIONS
I considered it of use to inform the scientific community of the rationale, the mechanism of action, the scientific basis and clinical findings of the DBM in order to encourage interest in the prospects opened up by the DBM through innovative formulations of the vitamins and Melatonin and the use of biological molecules with a high degree of antitumoural efficacy and low toxicity such as Somatostatin and its analogues.
Di Bella
Giuseppe
G
Di Bella Foundation, Bologna, Italy. posta@giuseppedibella.it
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use*; D004357:Drug Synergism; D006801:Humans; D008550:Melatonin / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D014815:Vitamins / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D000975:Antioxidants; D014815:Vitamins; D008550:Melatonin